# Edgewise Therapeutics Inc. (EWTX)

Source: https://www.quantisnow.com/company/EWTX
Generated: 2026-11-05T16:57:28.628Z

- Ticker: EWTX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2021
- SEC CIK: 0001710072
- Website: edgewisetx.com

## About

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was founded in 2017 and is headquartered in Boulder, Colorado.

## Latest EWTX news and filings

- 2026-11-05 13:00 UTC [Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring](https://www.quantisnow.com/insight/edgewise-therapeutics-announces-productive-end-of-phase-2-meeting-with-fda-for-6774865)
- 2026-11-04 21:01 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Edgewise Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-edgewise-therapeutics-inc-6772192)
- 2026-11-04 21:01 UTC [SEC Form 8-K] [Edgewise Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/edgewise-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6772190)
- 2026-11-04 21:01 UTC [Earnings] [Edgewise Therapeutics Reports Third Quarter 2026 Financial Results](https://www.quantisnow.com/insight/edgewise-therapeutics-reports-third-quarter-2026-financial-results-6772157)
- 2026-11-02 13:00 UTC [Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules](https://www.quantisnow.com/insight/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-6766225)
- 2026-10-16 12:39 UTC [Analyst Coverage Initiated] [William Blair initiated coverage on Edgewise Therapeutics](https://www.quantisnow.com/insight/william-blair-initiated-coverage-on-edgewise-therapeutics-6748776)
- 2026-10-08 12:00 UTC [Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400](https://www.quantisnow.com/insight/edgewise-therapeutics-doses-first-patient-in-phase-2-equinox-hfpef-trial-6741146)
- 2026-10-02 20:47 UTC [SEC Form 4] [Director Fox Jonathan C was granted 308 shares, increasing direct ownership by 1% to 25,141 units (SEC Form 4)](https://www.quantisnow.com/insight/director-fox-jonathan-c-was-granted-308-shares-increasing-direct-6735009)
- 2026-10-01 12:00 UTC [Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules](https://www.quantisnow.com/insight/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-6731509)
- 2026-09-22 11:00 UTC [Earnings Date] [Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500](https://www.quantisnow.com/insight/edgewise-therapeutics-unveils-the-differentiated-mechanism-of-action-moa-of-6722307)
- 2026-09-02 12:00 UTC [Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules](https://www.quantisnow.com/insight/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-6702382)
- 2026-08-24 12:00 UTC [Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026](https://www.quantisnow.com/insight/edgewise-therapeutics-announces-upcoming-late-breaking-science-presentation-at-the-european-6692141)
- 2026-08-17 22:41 UTC [SEC Form 4] [Amendment: SEC Form 4 filed by Chief Financial Officer Nofi Michael](https://www.quantisnow.com/insight/amendment-sec-form-4-filed-by-chief-financial-officer-nofi-6685585)
- 2026-08-17 22:41 UTC [SEC Form 4] [Amendment: SEC Form 4 filed by CMO Donovan Joanne M.](https://www.quantisnow.com/insight/amendment-sec-form-4-filed-by-cmo-donovan-joanne-m-6685583)
- 2026-08-17 22:40 UTC [SEC Form 4] [Amendment: SEC Form 4 filed by Chief Scientific Officer Russell Alan J](https://www.quantisnow.com/insight/amendment-sec-form-4-filed-by-chief-scientific-officer-russell-6685582)
- 2026-08-17 22:40 UTC [SEC Form 4] [Amendment: SEC Form 4 filed by General Counsel Moore John R](https://www.quantisnow.com/insight/amendment-sec-form-4-filed-by-general-counsel-moore-john-6685581)
- 2026-08-17 22:39 UTC [SEC Form 4] [Amendment: SEC Form 4 filed by Chief Business Officer Derakhshan Behrad](https://www.quantisnow.com/insight/amendment-sec-form-4-filed-by-chief-business-officer-derakhshan-6685580)
- 2026-08-14 20:54 UTC [SEC Form 4] [SEC Form 4 filed by Chief Financial Officer Nofi Michael](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-financial-officer-nofi-michael-6683505)
- 2026-08-14 20:53 UTC [SEC Form 4] [General Counsel Moore John R converted options into 12,499 shares and sold $219,823 worth of shares (5,016 units at $43.82), increasing direct ownership by 73% to 17,697 units (SEC Form 4) (for tax liability)](https://www.quantisnow.com/insight/general-counsel-moore-john-r-converted-options-into-12499-shares-6683497)
- 2026-08-14 20:54 UTC [SEC Form 4] [CMO Donovan Joanne M. converted options into 12,812 shares and sold $412,703 worth of shares (9,441 units at $43.71) as part of a pre-agreed trading plan, increasing direct ownership by 64% to 8,625 units (SEC Form 4) (for tax liability)](https://www.quantisnow.com/insight/cmo-donovan-joanne-m-converted-options-into-12812-shares-and-6683496)
- 2026-08-14 20:53 UTC [SEC Form 4] [Chief Scientific Officer Russell Alan J converted options into 12,812 shares and sold $258,042 worth of shares (5,901 units at $43.73), increasing direct ownership by 28% to 31,466 units (SEC Form 4) to satisfy withholding obligation](https://www.quantisnow.com/insight/chief-scientific-officer-russell-alan-j-converted-options-into-12812-6683495)
- 2026-08-14 20:53 UTC [SEC Form 4] [Chief Business Officer Derakhshan Behrad converted options into 13,281 shares and sold $223,424 worth of shares (5,100 units at $43.81), increasing direct ownership by 35% to 31,826 units (SEC Form 4) to cover taxes](https://www.quantisnow.com/insight/chief-business-officer-derakhshan-behrad-converted-options-into-13281-shares-6683487)
- 2026-08-14 20:52 UTC [SEC Form 4] [President and CEO Koch Kevin converted options into 39,844 shares and sold $785,042 worth of shares (17,971 units at $43.68), increasing direct ownership by 71% to 52,488 units (SEC Form 4) (withholding obligation)](https://www.quantisnow.com/insight/president-and-ceo-koch-kevin-converted-options-into-39844-shares-6683486)
- 2026-08-14 20:42 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Edgewise Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-edgewise-therapeutics-inc-6683432)
- 2026-08-13 20:31 UTC [SEC Form 144] [SEC Form 144 filed by Edgewise Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-edgewise-therapeutics-inc-6680897)
- 2026-08-06 14:20 UTC [SEC Form SCHEDULE 13G filed by Edgewise Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-edgewise-therapeutics-inc-6667986)
- 2026-08-06 12:05 UTC [SEC Form 8-K] [Edgewise Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/edgewise-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6667519)
- 2026-08-06 12:05 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Edgewise Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-edgewise-therapeutics-inc-6667515)
- 2026-08-06 12:00 UTC [Edgewise Therapeutics Reports Second Quarter 2026 Financial Results](https://www.quantisnow.com/insight/edgewise-therapeutics-reports-second-quarter-2026-financial-results-6667459)
- 2026-07-17 20:24 UTC [SEC Form 4] [SEC Form 4 filed by Director Root Jonathan D](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-root-jonathan-d-6641169)
- 2026-07-16 12:01 UTC [SEC Form 8-K] [Amendment: Edgewise Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits](https://www.quantisnow.com/insight/amendment-edgewise-therapeutics-inc-filed-sec-form-8-k-financial-statements-6639083)
- 2026-07-13 12:37 UTC [SEC Form 8-K] [Edgewise Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/edgewise-therapeutics-inc-filed-sec-form-8-k-completion-of-acquisition-6634932)
- 2026-07-13 12:30 UTC [Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline](https://www.quantisnow.com/insight/edgewise-therapeutics-completes-sale-of-sevasemten-for-up-to-265-6634920)
- 2026-07-13 12:30 UTC [Mergers & Acquisitions] [Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business](https://www.quantisnow.com/insight/servier-completes-the-acquisition-of-edgewise-therapeutics-muscular-dystrophy-business-6634917)
- 2026-07-09 13:27 UTC [Analyst Coverage Initiated] [Oppenheimer initiated coverage on Edgewise Therapeutics with a new price target](https://www.quantisnow.com/insight/oppenheimer-initiated-coverage-on-edgewise-therapeutics-with-a-new-price-6632669)
- 2026-07-02 21:21 UTC [SEC Form 4] [Chief Scientific Officer Russell Alan J exercised 200,000 shares at a strike of $0.36 and sold $7,881,402 worth of shares (200,000 units at $39.41) (SEC Form 4)](https://www.quantisnow.com/insight/chief-scientific-officer-russell-alan-j-exercised-200000-shares-at-6626433)
- 2026-07-01 23:46 UTC [SEC Form 4] [Director Fox Jonathan C was granted 319 shares, increasing direct ownership by 1% to 24,833 units (SEC Form 4)](https://www.quantisnow.com/insight/director-fox-jonathan-c-was-granted-319-shares-increasing-direct-6623861)
- 2026-07-01 20:55 UTC [SEC Form 144] [SEC Form 144 filed by Edgewise Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-edgewise-therapeutics-inc-6623416)
- 2026-07-01 12:00 UTC [Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules](https://www.quantisnow.com/insight/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-6621911)
- 2026-06-17 21:14 UTC [SEC Form 4] [SEC Form 4 filed by Director Brege Laura](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-brege-laura-6607224)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/EWTX
- Earnings history: https://www.quantisnow.com/earnings/EWTX
- Dividend history: https://www.quantisnow.com/dividends/EWTX
- Insider transactions: https://www.quantisnow.com/insiders/EWTX
- Options chain: https://www.quantisnow.com/options/EWTX
- SEC 8-K filings only: https://www.quantisnow.com/company/EWTX/8-k
- RSS and alerts for EWTX: https://www.quantisnow.com/docs/rss-feeds.md